NRX Pharmaceuticals Aktie

NRX Pharmaceuticals für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A4091K / ISIN: US6294442099

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
26.08.2025 17:13:41

EQS-News: NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem

EQS-News: Benzinga / Key word(s): Science
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem

26.08.2025 / 17:13 CET/CEST
The issuer is solely responsible for the content of this announcement.


By Meg Flippin Benzinga

DETROIT, MICHIGAN - August 26, 2025 (NEWMEDIAWIRE) - Dr. Jonathan Javitt, CEO of NRx Pharmaceuticals Inc. (NASDAQ: NRXP), was recently a guest on Benzinga’s All-Access. 

68adab2eda846f1ee0626d87_1

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program, NRX-101, is an oral, fixed-dose combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor. 

Depression and suicide are centuries-old problems in need of modern-day treatments, and that’s what NRx believes it has with NRX-101 and NRX-100. Both drugs target the loss of neuroplasticity in the brain, which research has shown leads to depression and suicide ideation. 

“Suicidality is the loss of plasticity in the brain,” Javitt told Benzinga during the interview, noting that a loss of plasticity causes frequent depressive states and is associated with PTSD and suicide depression. “All of these drugs we are so excited about, whether it's Kentamine, which is NRX-100, or D-cycloserine, which is NRX-101, upregulate neuroplasticity. It causes the brain to make new connections.” 

NRX-100 just got Fast Track designation from the U.S. FDA  for the treatment of suicidal ideation in patients with depression. The drug already has that FDA designation for the treatment of suicidal bipolar depression. Javitt said the new designation takes its potential market from about 1 million to the 13 million U.S. adults the CDC says consider suicide each year. 

Outside of developing drugs to treat depression and suicide ideation, NRX is opening treatment clinics across the country through its HOPE Therapeutics subsidiary. 

Watch the full interview here: 
https://www.youtube.com/watch?v=AFNU5Jr7g7A

Featured image from Shutterstock.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.


News Source: Benzinga


26.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Benzinga
United States
ISIN: US6294442099
EQS News ID: 2188932

 
End of News EQS News Service

2188932  26.08.2025 CET/CEST

Analysen zu NRX Pharmaceuticals Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

NRX Pharmaceuticals Inc Registered Shs 3,27 -1,80% NRX Pharmaceuticals Inc Registered Shs